Intellia Therapeutics Inc. is a Intellia Therapeutics Inc is a genome editing company. It is focused on developing proprietary, potentially curative CRISPR/Cas9-based therapeutics.
Intellia Therapeutics Inc. (NTLA) had a good day on the market for Tuesday March 30 as shares jumped 10.61% to close at $72.24. About 2.06 million shares traded hands on 25,372 trades for the day, compared with an average daily volume of n/a shares out of a total float of 67.73 million. After opening the trading day at $64.85, shares of Intellia Therapeutics Inc. stayed within a range of $72.80 to $61.78.
With today’s gains, Intellia Therapeutics Inc. now has a market cap of $4.89 billion. Shares of Intellia Therapeutics Inc. have been trading within a range of $92.00 and $11.03 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Intellia Therapeutics Inc is a genome editing company. It is focused on developing proprietary, potentially curative CRISPR/Cas9-based therapeutics. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema, and ex vivo programs which include Acute Myeloid Leukemia.
Intellia Therapeutics Inc. is based out of Cambridge, MA and has some 312 employees. Its CEO is John M. Leonard.